Skip to main content

Table 2 Ongoing clinical trials for TNBC: Different class of agents are being tested (eg. Anti-PD1- Pembrolizumab) on different subjects (eg. metastatic TNBC) and given in combination with other chemotherapeutic agents as the promising immunotherapy for TNBC treatment. These trials are approved with identifier and are in different phase of their evaluation with their probable compeltion date

From: Recent advances in nanotheranostics for triple negative breast cancer treatment

Class of agents

Agent

Phase

Participants

Combinatorial agent

Completion

Identifier

AR antagonist

Enzalutamide

2

Stage I-III AR positive TNBC

-

April 2019

NCT02750358

Anti-PD1

Pembrolizumab

1/2

Recurrent TNBC, mTNBC

PLX3397 (TkI of KIR, CSFIR)

May 2019

NCT02452424

Anti-PD1

Pembrolizumab

2

mTNBC

Carboplatin + gemcitabine

June 2019

NCT02755272

Hsp90 inhibitors

Onalespib

1

Metastatic solid tumor, Recurrent TNBC

Olaparib

October 2019

NCT02898207

AR antagonist

Enzalutamide

1/2

AR positive mTNBC

Taselisib (PI3K inhibitor)

December 2019

NCT02457910

Anti-PD1

Pembrolizumab

3

Recurrent TNBC and mTNBC

Nab-paclitaxel /Paclitaxel/gemcitabine/

carboplatin

December 2019

NCT02819518

PARPi

Olaparib

3

TNBC, Germline BRCA1/2 mutation

-

March 2020

NCT02032823

PARPi

Olaparib

1b

Recurrent TnBc

AZD2014 (mTORC1/2 inhibitor)

November 2020

NCT02208375

AR antagonist

Enzalutamide

2

AR positive mTNBC

Paclitaxel

December 2020

NCT02689427

Anti-PD1

Pembrolizumab

2

Advanced TNBC or mTNBC

-

January 2021

NCT02644369

Anti-PD-L1

MPDL3280A

2

TNBC

Nab-paclitaxel

February 2021

NCT02530489

Anti-PD1

Pembrolizumab

1/2

mTNBC

Paclitaxel

May 2021

NCT02734290